Oxford Cancer Analytics (OXcan) has signed for 2,400 sq ft of space at Mission Street and BGO’s Inventa building in Oxford’s West End.
Founded in 2019, OXcan is moving from the BioEscalator to Inventa and joins a growing number of innovation companies at the cluster.
Colin Brown, development director at Mission Street, said: “We’re delighted to welcome OXcan as the newest occupier at Inventa. They are an exceptional company advancing the science of machine learning and diagnostics. OXcan is a valuable addition to the growing Inventa and West End ecosystem. Inventa is now nearing full occupancy, bringing together some of Oxford’s most exciting innovation companies and establishing the city’s only central research and development cluster.”
Dr Andreas Halner, OXcan’s president and co-founder, added: “The new facility will enable OXcan to expand its analytical and laboratory capabilities, strengthen clinical collaborations and advance our mission to deliver more accurate and accessible diagnostics to patients worldwide.
“We chose Inventa for its convenient proximity to central Oxford and the train station, offering access to top talent from Oxfordshire and beyond. The Mission Street team has been outstanding in supporting our transition, and we look forward to this next phase of growth and to contributing to the dynamic innovation ecosystem taking shape in Oxford’s West End.”
